Calliditas Therapeutics announced that the European Commission has granted a full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy. The European Commission has granted a full marketing authorization of Kinpeygo. Kinpeygo is marketed in in the European Union and UK exclusively by Calliditas’ commercial partner, Stada Arzneimittel. This approval triggers a milestone payment of EUR 10M to Calliditas, which will be recognized as revenue in Q3.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- Calliditas says partner initiated Phase III Nefecon trial in Japan
- Calliditas Therapeutics announces USPTO issues patent for setanaxib
- Calliditas Therapeutics’ Annual Meeting Highlights
- Calliditas Therapeutics downgraded to Hold from Buy at Pareto
- Calliditas Therapeutics downgraded to Hold from Buy at SEB Equities
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue